Diabetic Retinopathy Diagnosis Device
Small Business Information
NEURO KINETICS, INC., 128 GAMMA DR, PITTSBURGH, PA, 15238
AbstractDESCRIPTION (provided by applicant): The long-term objective of this application is to develop an imaging device for the early detection, diagnosis and quantification of the degree of midperipheral retinal ischemia in Diabetic Retinopathy (DR). DR is one of the more debilitating potential outcomes of diabetes posing a major threat to the quality of life of diabetics. Experts believe that DR is the leading cause of blindness in the industrialized world in people between the ages of 25 and 74 years old. The American Academy of Ophthalmology states that DR is the leading cause of blindness among working Americans and currently affects nearly seven million people in the U.S. Early detection can help treat DR and salvage about 90 percent of vision loss, but abou t one-third of the diabetic population remains undiagnosed, translating into approximately 5.7 million people in the U.S. Delay in the primary diagnosis of diabetes allows diabetic complications to progress significantly before detection further increasing the risks associated with the disease by making the treatment much more complicated. Diabetes management guidelines advocate initiation of therapeutic intervention early in the prognosis of the disease. Estimates of diabetics in the U.S. with DR range fro m 15% to as high as 40%. The goal of Neuro Kinetics diabetic screening methodology is to detect the primary effects of DR or secondary phenomena that are the direct result of vascular damage, well before the patients develop proliferative DR or severe diab etic macular edema. To develop a prototype imaging device using a combination of analytical and experimental methods to validate the imaging device will include the following specific aims: (1) develop the prototype imaging hardware for early detection, di agnosis, and quantification of the degree of midperipheral retinal ischemia in DR - the most significant issue is the hardware design of the system; (2) develop prototype software that will modify Neuro Kinetics existing I-Portal(tm) software and supplemen t it with DR screening specific stimulus presentation and results analysis software; 3) perform proof-of-concept testing on a limited sample of normal and advanced DR patients; and 4) analyze data and prepare a Phase II SBIR plan to assess the sensitivity and specificity of the testing algorithm over a full range of severity of DR. Earlier diagnosis of DR could facilitate intervention at a stage that may prevent or lessen permanent damage from the ravages of the disease in turn, improving patient quality of life and reducing lifetime treatment costs. Experts believe that Diabetic Retinopathy is the leading cause of blindness in the industrialized world in people between the ages of 25 and 74 years old. There is wide spread agreement that our current eye care delivery system cannot meet the screening needs of these patients by relying on traditional clinical eye examinations by eye care professionals. Neuro Kinetics proposes to develop a rapid, noninvasive screening technology based on images of how the eye re sponds to unique patterns of light to increase the opportunity for earlier diagnosis.
* information listed above is at the time of submission.